Real-World Data of Tenecteplase Versus Alteplase in the Treatment of Acute Ischemic Stroke: A Single-Center Analysis
Authors: Yao Yu , Zhang Xiaoqin , Liu Chang , Cai Lingling , Ying Yisha , Wu Yuefei , Yang Jianhong 
Published: January 2024

BACKGROUND AND PURPOSE

Tenecteplase was demonstrated pharmacological superiority over alteplase, potentially translating into clinical benefits. Numerous studies have confirmed that the effectiveness and safety of tenecteplase in acute ischemic stroke (AIS) treatment may not be inferior to that of alteplase, and it has potential workflow advantages. This study aimed to evaluate whether tenecteplase’s use in routine clinical practice has time management advantages and corresponding clinical benefits.

METHODS

The study included AIS patients treated with alteplase at the first affiliated Hospital of Ningbo University from January 2022 to February 2023, and those treated with tenecteplase from March 2023 to November 2023. We compared baseline clinical characteristics, key reperfusion therapy time indices (onset-to-treatment time [OTT], door-to-needle time [DNT], and door-to-puncture time [DPT]), and clinical outcomes (24-hour post-thrombolysis National Institutes of Health Stroke Scale [NIHSS] improvement, and intracranial hemorrhage incidence) between the groups using univariate analysis. We also assessed hospital stay durations and used binary logistic regression to examine tenecteplase’s association with DNT and DPT target times, NIHSS improvement, and intracranial hemorrhage.

RESULTS

120 patients treated with tenecteplase and 144 with alteplase were included in the study. Baseline characteristics showed no significant differences in demographic data (sex and age), vascular risk factors (body mass index, hypertension, diabetes), baseline NIHSS, mRS, and bridging thrombectomy (P > 0.05). However, the tenecteplase group had a higher prevalence of hyperlipidemia (21.7% vs. 12.5%, P=0.047) and a lower incidence of atrial fibrillation (21.7% vs. 34%, P=0.027). Key time indices for AIS reperfusion therapy, such as OTT (133 vs. 163.72, P=0.001), DNT (36.5 vs. 50, P < 0.001), and DPT (117 vs. 193, P=0.002), were significantly faster in the tenecteplase group. Additionally, the rates of DNT ≤ 45 min (65.83% vs. 40.44%, P < 0.001) and DPT ≤ 120 min (59.09% vs. 13.79%, P=0.001) were significantly higher in the tenecteplase group compared to the alteplase group. Tenecteplase was an independent predictor of achieving target times for DNT (OR 2.951, 95% CI 1.732-5.030; P < 0.001) and DPT (OR 7.867, 95% CI 1.290-47.991; P=0.025). Clinically, the proportion of patients with NIHSS improvement 24 hours post-thrombolysis was significantly higher in the tenecteplase group (64.17% vs. 50%, P=0.024). No significant differences were observed in the incidences of symptomatic intracranial hemorrhage (sICH) or any intracranial hemorrhage (ICH) (P > 0.05). Patients receiving tenecteplase had shorter hospital stays (6 vs. 8 days, P < 0.001). In binary logistic regression models, tenecteplase was an independent predictor of NIHSS improvement at 24 hours (OR 1.715, 95% CI 1.011-2.908; P=0.045). There was no significant association between thrombolytic choice and sICH or any ICH (P > 0.05).

CONCLUSIONS

Venous thrombolysis with tenecteplase in AIS treatment significantly reduced DNT and DPT. It was associated with early neurological function improvement (at 24 hours), without compromising safety compared to alteplase. Shorter length of hospital stays for patients were found in the tenecteplase group. The findings support tenecteplase’s application in AIS as a new treatment choice.